618. Acute Myeloid Leukemias: Biomarkers and Molecular Markers in Diagnosis and Prognosis: Poster III

Soluble immune modulators in the bone marrow microenvironment predict long term survival in pediatric de novo AML An olink based proteomic and transcriptomic study

CD15 expression on leukemic cells associates with extramedullary infiltration and adverse outcomes in Acute Myeloid Leukemia

RNA fusion sequencing identifies clinically relevant and novel fusions with therapeutic implications in adults with Acute Myeloid Leukemia AML

From theory to therapy Predicting response to chemotherapy with multiomic longitudinal profiling of peripheral blood in AML

Targeting ABCD1 inhibits peroxisomal fatty acid oxidation to selectively eliminate Acute Myeloid Leukemia cells

Myeloid malignancies molecular analysis for therapy choice myeloMATCH Rapid availability of clinical pathologic and molecular features for treatment assignment in the first 550 patients

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML MDS patients with del 5q complex karyotype an NCI myelomatch and SWOG report

Heterogeneity of immune escape mechanisms in de novo Acute Myeloid Leukemia

Prognostic implications of commutational patterns in NPM1 mutated AML receiving intensive treatment cetlam group study

Quantifying treatment associated monocytic differentiation in AML using a single cell based myeloid differentiation index MDX

Refined genetic risk model with complex karyotype predicts outcomes of newly diagnosed acute myeloid leukemia treated with decitabine plus venetoclax

Low levels of wilms tumor 1 WT1 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

Protein levels of isocitrate dehydrogenase 1 and 2 are prognostic and independent of mutation status in acute myelogenous leukemia

Next generation sequencing profiling of pediatric Acute Myeloid Leukemia reveals distinct genetic landscapes across cytogenetic subgroups

TP53 mutated Acute Myeloid Leukemia through a single cell lens

Silibinin enhances daunorubicin chemosensitivity in Acute Myeloid Leukemia by suppressing PDIA3 mediated autophagy

Early peripheral blood blast clearance is a prognostic marker for early treatment response and long term outcome in pediatric Acute Myeloid Leukemia

Single cell multiomics reveals candidate cis regulatory elements in NPM1 mutant AML

Low levels of enhancer of zeste homolog 2 EZH2 protein are prognostically adverse and independent of mutation status in acute myelogenous leukemia

High protein expression of MDS1 and EVI1 complex locus MECOM is prognostically adverse and independent of chromosome 3 rearrangements in acute myelogenous leukemia

Sensitive detection of novel structural variants and 3D chromosome conformation reveals likely novel drivers including enhancer hijacking in AML

FLT3 CD135 expression in pediatric AML is associated with specific disease characteristics and worse outcome in the setting of sorafenib theraphy A report from the Children s Oncology Group AAML1031 protocol

Mitochondrial suppression in Acute Myeloid Leukemia and Myelodysplastic Syndromes A two cohort transcriptomic analysis using GEO

Association between clonal mutations in Acute Myeloid Leukemia and novel fibrinolytic biomarkers

Developing transcriptomic signature for IDH1 and IDH2 acute leukemia and the demonstration of high prevalence of these signatures in mutation negative leukemia

Prognostic impact of co occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia Insights from real world genomic data

Additional genetic targets are present in the majority of AML patients with NPM1 KMT2A or NUP98 aberrations potentially impacting combination therapy with menin inhibitors

Validation of the FL IL6 score a new dynamic cytokine based risk model in adults with acute myeloid leukemia a prospective multicentre filo study

HOXA9 METTL3 BMI1 axis is required for promoting anthracycline resistance in acute myeloid leukemia cells by modulating BMI1 expression through  mRNA m6A modification

Interim results of a multi center clinical trial evaluating copy number aberrations via shallow whole genome sequencing LeukoPrint in Acute Myeloid Leukemia